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The American Geriatrics Society convened a conference in
Bethesda, Maryland, to explore models and studies of
aging. This was the second of three conferences, supported
by a U13 grant from the National Institute on Aging, to aid
recipients of Grants for Early Medical/Surgical Specialists
Transition to Aging Research (GEMSSTAR) in integrating
geriatrics into their specialties. Recognizing that aging is the
largest risk factor for multiple chronic diseases and age-
related loss of resilience, the conference organizers focused
scientific sessions on how targeting age-related mechanisms
can delay, prevent, or reverse geriatric syndromes, age-
related chronic diseases, and loss of resilience. The rationale
for studying models of aging as well as study designs,
strategies, and challenges of studying human aging were
reviewed. This article provides a summary of the full con-
ference report, Models and Studies of Aging: Report from
the U13 Conference Series, and summarizes key take-home
messages that were designed to support GEMSSTAR
awardees in developing their research careers focused on
aging research (see supplementary text for the full report).
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On September 21-23, 2016, the American GeriatricsSociety convened a conference in Bethesda, Maryland,
to explore models and studies of aging. This was the second
of three conferences, supported by a U13 grant from the
National Institute on Aging (NIA) that focuses on assisting
recipients of Grants for Early Medical/Surgical Specialists
Transition to Aging Research (GEMSSTAR) to integrate
geriatrics into their subspecialties. The GEMSSTAR pro-
gram builds on the success of two programs that were
funded by the Atlantic Philanthropies and the John
A. Hartford Foundation, Inc. (the T. Franklin Williams and
Dennis W. Jahnigen Scholars Awards).1–3 The goals for each
of the U13 conferences were twofold. The first goal was to
introduce participants to key concepts and approaches that
are important to understand when undertaking research on
aging. The second goal was to help GEMSSTAR awardees
prepare for the next stage of their research careers and to
build the GEMSSTAR collaborative network. Drs. James
Kirkland, of the Mayo Clinic, and Raymond Yung, of
the University of Michigan, served as co-chairs for this
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conference.4 A total of 110 people representing 19 specialties
attended the meeting (Table 1). This article provides a high-
level overview of the full conference report, Models and
Studies of Aging: Report from the U13 Conference Series
(see supplementary text for the full report), and it offers
thoughts on contributions that the GEMSSTARs could
make to future research progress.
RATIONALE FOR STUDYING MODELS OF AGING:
THE GEROSCIENCE HYPOTHESIS
The rationale for studying models of aging is based on the
geroscience hypothesis: targeting fundamental aging pro-
cesses will delay, prevent, alleviate, or reverse multiple geri-
atric syndromes, chronic diseases, and loss of resilience.
Despite the complexity and variability in aging, it is hypoth-
esized that aging is driven by interconnected biological
mechanisms called the hallmarks or pillars of aging: geno-
mic instability, telomere attrition, epigenetic alterations, loss
of proteostasis, deregulated nutrient sensing, mitochondrial
dysfunction, cellular senescence, stem cell exhaustion, and
altered intercellular communication.5 Disruptions in one or
several of these hallmarks of aging contribute to the devel-
opment of chronic diseases and/or frailty. At present, geriat-
ric medicine focuses on tertiary prevention, managing
complications of chronic diseases and geriatric syndromes.
However, interventions that target fundamental aging pro-
cesses will likely be most useful if they are administered
before the beginning of disability. With this approach,
advances in the biology of aging could lead to interventions
that compress morbidity and delay chronic diseases and
geriatric syndromes.
Several interventions that target these hallmarks of
aging are making their way from basic biology studies in
animals through early translation studies. Throughout the
U13 conference, specific considerations in the development
of intervention studies targeting aging processes or age-
associated diseases were discussed (Table 2). First, preclini-
cal models should include aged or frail animals, those fed
high-fat diets, models of resilience, and other models
exposed to clinically relevant insults. Likewise, toxicity test-
ing requires age-appropriate models and should address
short- and long-term toxicity and be acceptable to the Food
and Drug Administration (FDA) for inclusion in investiga-
tional new drug (IND) applications. When moving interven-
tions from preclinical testing to clinical trials, investigators
should test effects on measurable, clinically relevant
outcomes that are appropriate for older populations. Stud-
ies of agents targeting aging processes should assess effects
on panels of mechanistic biomarkers related to the hall-
marks of aging. Finally, trials testing agents that target
aging processes might be served better by enrolling older
participants, particularly those with multiple comorbidities.
However, emerging evidence from cohort studies suggests
the need for intervention at earlier time points in the disease
process, but the best time for evaluation and effective inter-
vention remains unclear.
In addition to standard phase I, II, and III clinical trials,
the concept of pragmatic clinical trials was discussed as an
attractive option for studying older adults. They are designed
to inform healthcare decision makers that can include
patients, clinicians, and policymakers. They compare clini-
cally relevant alternatives, enroll diverse study populations
from the real world, recruit from several practice settings,
and measure a broad range of relevant health outcomes or
streamline data collection to ensure adequate power.6 Prag-
matic clinical trials differ from explanatory trials by offering
broader eligibility, flexible interventions, typical practi-
tioners, no follow-up visits, and usual adherence.7
STRATEGIES AND CHALLENGES IN CLINICAL
TRIALS TARGETING HUMAN AGING
Strategies, challenges, and frameworks for proof-of-concept
and clinical trials of interventions derived from studies in
aging biology were discussed at an R24 geroscience retreat
that brought together members of the Geroscience Network
funded by the National Institutes of Health.8 Major themes
that emerged from these discussions were summarized for
the GEMMSTAR scholars (Table 2).
Target Big-Picture Outcomes
Not only is aging the primary nonmodifiable risk factor for
several chronic diseases, it is also the prism or processor
that determines how diseases manifest in people’s lives.
Thus clinical studies in aging should focus on integrative
big-picture outcomes that are important to people’s lives,
such as functional outcomes and independence, geriatric
syndromes, and mortality. The workshops recommended
extending the health span as one framework, where target-
ing the mechanisms underlying aging could prevent or delay
the losses and declines associated with aging, and studies
would assess global outcomes such as multimorbidity or
daily function. Enhancing resilience was also recommended
as a framework. At every level, from the cellular and molec-
ular level to the whole person, aging presents universally as
a weakened ability to cope with new stresses and stimuli.
Within this framework, interventions that target the mecha-
nisms of aging could reduce the period of decline or
enhance the period of recovery following stress, again at
various levels.
Study an Aging Population
Most clinical studies still look for ideal participants, for
example patients with no comorbidities.9 Although there is
some mechanistic value to studying interventions in the
ideal population, these agents also should be studied in
Table 1. Represented Specialties
Anesthesiology Nephrology
Cardiology Obstetrics and gynecology
Emergency medicine Ophthalmology
Endocrinology Palliative medicine
Gastroenterology Physical medicine and
rehabilitation
General internal medicine Psychiatry
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Table 2. Topics, Speakers, and Take-Away Themes
Topic Speaker Key take-away theme
Biology of aging
Pillars of Aging Luigi Ferrucci, MD, PhD,
National Institute on Aging
• Importance of studying resilience, as well as decline
• Variability and complexity among older adults
• Need for the FDA to specify aging mechanisms and
multimorbidities as indications for treatment and end points for
clinical studies
Inflammation Jeremy Walston, MD,
Johns Hopkins University
School of Medicine
Metabolism Nick Musi, MD, Barshop
Institute





Thomas Rando, MD, PhD,
Stanford University
• Need for flexibility and taking advantage of unexpected
developments
Trials: Phase I and II James Kirkland, MD, PhD,
Mayo Clinic
Trials: Phase III Nir Barzilai, MD, Albert
Einstein College of
Medicine




James Kirkland, MD, PhD,
Mayo Clinic
• Target big-picture outcomes.
• Clinical trials should include older people, particularly those who
are frail or have multiple morbidities, and embrace heterogeneity.
• Need for infrastructure, including assistance with preparing
investigational new drug applications, to facilitate translation of
basic science discoveries to the clinic
Research methods and strategies
Pragmatic Trials Marcel Salive, MD, MPH,
NIA Division of Geriatrics
and Clinical Gerontology
• Prioritizes comparing clinically relevant alternatives in diverse study
populations from real-world practice settings
• Increasing opportunities for pragmatic trial designs in frailty,
disability, and multiple chronic comorbidities because <15% of
guidelines are based on high-quality evidence
Finding Research
Questions
Josie Briggs, MD, NIA
Aging Research for the
Specialties
• Focus questions on conventional wisdom and the supporting
evidence
• Incomplete knowledge stems from inadequate biological
understanding, inappropriate outcome measures, insufficient high-
quality data, or efficacy data with limited external validity or
heterogeneous effects, as well as failure to weigh potential harms
with benefits
• The Precision Medicine Initiative offers an opportunity to inform a
broad variety of research studies and a transformational approach
to diversity
The Continuing Value of
Clinician Investigators
Evan Hadley, MD, Director
of the National Institute on
Aging
• Specialty clinical investigators remain essential to better
understanding the role of aging mechanisms in age-related
conditions, the bidirectional interactions of multimorbidities, earlier
targeting of chronic disease or risk factors as prevention, and





Joachim Ix, MD, MAS,
University of California,
San Diego
• Existing data set projects can increase collaborative research
productivity with potential for ancillary studies
• Large epidemiological studies often have topic-oriented working
groups and statistical support to provide advice on ideas,
manuscripts, and career
• Disadvantages include administrative complexities, limited data and





PhD, National Institute on
Aging
• Established as a lifelong cohort study of normative aging in 1958
with updates in 2004 and 2011 to characterize various aspects of
the aging process and interactions through biannual (ages 60-79)
or annual assessment of core and advanced measures
• End points include life expectancy, health longevity, mobility,
cognitive impairment, and frailty
• Aims to be responsive to emerging research questions in aging
with opportunities for translational studies
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Table 2 (Contd.)
Topic Speaker Key take-away theme
Health and Retirement
Study (HRS)
Alex Smith, MD, University
of California, San
Francisco
• HRS includes biennial surveys since 1992, about 20 000
participants
• Provide focus on the relationship of financial and social status with
health
• Access to functional status and cognition, health services use,




Dalane Kitzman, MD • Anticipate a path filled with challenges rather than a straight path of
early and sustained success
• Select an important question and the answers will matter
regardless of the results
• “Mistakes” offer best clues from which to adapt in relentless pursuit
of truth
• Enjoy the journey of discovery
After the R03: Scaling Up
Your Research Program
Robin Barr, D. Phil • Contemplate three paths simultaneously: career development,
research, and organizing a field
• These three paths are not necessarily independent
• NIA career development awards include K08, K23, and
Beeson K76





PhD, National Institute on
Aging
• Develop a graphic illustration of the conceptual framework of your
science to orient “consumers” of your proposal
• Seek critical feedback on gaps in your rationale
• Focus communication on the take-home message
• Harness expertise of seasoned administrators to navigate your
organization’s human resources game
• Develop winning negotiation strategies by illustrating the value of
your request for the organization and providing a clear plan for
resources
Table 3. Future Specialty Clinician Investigators’ Contributions to Progress
Topic Specialty clinician educator future contributions
Role of aging mechanisms in age-related
conditions
• Development of mechanism-proximal markers and targets and relating them to
multiple aging phenotypes
• Knowledge about favorable and unfavorable clinical effects of interventions
targeting particular aging mechanisms and pleiotropy in the effects of aging
mechanisms on multiple outcomes
• Application of new technologies, such as imaging and other noninvasive measures
Multimorbidity • Knowledge about the bidirectional interactions between aging mechanisms and
age-related conditions
• How one age-related morbidity might influence the progression of others through
effects on aging mechanisms
• The interactions among specific disease combinations and their treatments
• The trade-offs between the potential benefits and harms of interventions
Prevention • Knowledge about the implications of research participant selection; the
development of screening methods
• The potential for expanding the role of tests that might detect early stages of aging
pathology
• The sensitivity, specificity, and clinical impact of new screening or diagnostic tests
in patients of differing ages and comorbidities
• The value of linking with epidemiological studies, and integrating information from
clinical encounters with data from longitudinal studies to improve understanding of
modifiable risk factors for aging outcomes
Healthcare quality measures and
evidentiary bases for payment
• Development of appropriate performance and outcome measures for patients with
multimorbidities and integrating them with disease-specific measures
• Assess the relative clinical value of new diagnostic tests or interventions,
compared with alternatives, and evidence-based indications for which patients
should receive them
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populations that will actually be treated. Clinical trials
should include older people, particularly those who are frail
or have multiple morbidities, and embrace heterogeneity.
The choice of study population will depend on the interven-
tion under study, the presence and severity of illness and
how that affects outcomes of interest, and the window of
opportunity for intervention. Small pilot studies should be
conducted to determine the best time and approach for
applying interventions. In addition, clinical studies should
be considered within the overall context of aging: how the
disease of interest is affected by the hallmarks of aging,
their biochemical markers, and the interactions among
them; how the disease of interest is influenced by other
chronic diseases, and what markers should be used to mea-
sure them; and which global outcomes should be measured.
New Tools for Helping Older Adults
Studies in aging biology could yield new interventional
tools that clinicians can use to affect their disease of inter-
est. Among potential interventions emerging from basic and
clinical studies are those such as metformin, acarbose, angio-
tensin receptor blockers, and angiotensin-converting enzyme
inhibitors that are already approved by the FDA but could
play broader roles in aging. However, many agents have not
been tested specifically in frail or older adults. Existing clinical
programs targeting older adults can be leveraged to provide
infrastructure and comparisons in clinical studies. These tools
and clinical studies can also contribute to an evidence base to
support aging as an indication on which the FDA could base
approvals of interventions. Composites of existing outcomes,
for example multiple diseases, could also be used.
Accelerating Translation
Workshop discussions also focused on how to facilitate the
incorporation of aging into clinical studies. Suggestions
included the development of cognitive and physical infrastruc-
ture to accelerate research; subspecialists’ integration of aging
concepts into their studies; a shared library of templates for
trial designs, INDs, institutional review board proposals, and
data safety monitoring board reports adapted to older adults
and aging-related outcomes; a standardized modular outcome
toolkit; and a national geroscience biobank that is diverse
and enriched for multimorbidity and frailty.
FUTURE OF AGING RESEARCH: OPPORTUNITIES
FOR GEMSSTAR TO CONTRIBUTE TO PROGRESS
Over the next decades, as the US population ages, specialty
clinician investigators will contribute to an evolution of
progress in several areas. Discussions throughout this meet-
ing emphasized the value of interspecialty collaboration in
aging research (Table 2). Stimulating interspecialty collabo-
ration could prove powerful and lead the nation in revolu-
tionizing care, particularly because of the pleiotropic nature
of aging-related mechanisms.
In the closing plenary, NIA’s Dr. Evan Hadley
highlighted some of the areas where he believes specialty cli-
nician investigators are particularly well positioned to con-
tribute to future progress (Table 3). He emphasized that
interspecialty collaborations will be particularly important
to future progress and encouraged GEMSSTAR awardees
to think broadly about collaboration and how best to pro-
mote it. He advised GEMSSTAR awardees to embrace flexi-
bility, leverage unexpected developments, and envision how
research can evolve beyond the next short-term study,
emphasizing key points that had emerged from prior pre-
sentations. He noted that clinician investigators bring a par-
ticular value to aging research, including the following:
• Their experience in technology and technology
development for assessing human biology and func-
tion in vivo;
• Experience in and ability to collaborate with preclin-
ical researchers, ongoing disease-focused research on
the mechanisms underlying aging;
• Knowledge of real-world constraints on the feasibil-
ity of translating an intervention; and
• Their ability to assess the whole patient as opposed
to a target organ.
Finally, the scholars were reminded that the translation
of a discovery from the bench to the bedside rarely follows
a linear pattern, and conference participants were encour-
aged to embrace this winding path with unexpected turns
that can potentially be the path to breakthroughs to
improve the quality of care for an aging population.
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